Aldeyra Therapeutics (ALDX) said its experimental drug ADX-629 showed statistically significant improvement in liver function among patients with mild to moderate alcohol-associated hepatitis in a mid-stage trial. The oral treatment was well tolerated, with no serious or drug-related adverse events reported.